![The sights of Avalon Air Show 2025: Day Three [PHOTOS]](https://breakingdefense.com/wp-content/uploads/sites/3/2025/03/f-35-avalon-final-day-scaled-e1743079275404.jpg?#)
.jpg)
Fierce Pharma Asia—Novo's triple G obesity bet; Merck's latest China deal; Hengrui, Elevar's 2nd FDA snub
Novo Nordisk snagged an obesity asset from China's United Laboratories for up to $2 billion. Merck got an lp(a) inhibitor from Hengrui for cardiovascular disease. Hengrui and Elevar's PD-1 liver cancer combo was again tripped up by manufacturing at the FDA.
Novo Nordisk snagged an obesity asset from China's United Laboratories for up to $2 billion. Merck got an lp(a) inhibitor from Hengrui for cardiovascular disease. Hengrui and Elevar's PD-1 liver cancer combo was again tripped up by manufacturing at the FDA.
